


Eves et al., <http://www.jcb.org/cgi/content/full/jcb.201201024/DC1>

Figure S1. Surface residues on Myo2 that comprise the Vac17 and Mmr1 binding sites. (A) *myo2-P1529S* is the sole mutation in *myo2-573* that disrupts Myo2–Mmr1 interactions. (B) Actin cables are not affected in *mmr1Δ* or the *myo2* mutants tested. Wild-type, *mmr1Δ*, or *myo2* mutant strains were fixed and stained with phalloidin to visualize filamentous actin. Bar, 5 μ m. (C) Surface representation of the crystal structure of the Myo2 CBD. Colored residues indicate residues that were mutated and tested for Mmr1 or Vac17 interaction in a yeast two-hybrid test. Blue: binds Vac17 only; red: binds Mmr1 only; purple: binds Vac17 and Mmr1; green: mutations that did not perturb any of the interactions or phenotypes tested. Residues are indicated as follows: 1, 1,229; 2, 1,233; 3, 1,234; 4, 1,237; 5, 1,248 (*myo2-2*; internal residue); 6, 1,293; 7, 1,295; 8, 1,296; 9, 1,299; 10, 1,300; 11, 1,301; 12, 1,301; 13, 1,302; 14, 1,303; 15, 1,304; 16, 1,307; 17, 1,308; 18, 1,311; 19, 1,312; 20, 1,331; 21, 1,408; 22, 1,411; 23, 1,414; 24, 1,415; 25, 1,418; 26, 1,422; 27, 1,444; 28, 1,447; 29, 1,461; 30, 1,464; 31, 1,480; 32, 1,482; 33, 1,483; 34, 1,484; 35, 1,525; 36, 1,526; 37, 1,528; and 38, 1,529. Note that in the yeast two-hybrid test (Fig. 1), mutation of residues E1299Q and A1300G had a small effect on the interaction with Mmr1. However, the corresponding full-length mutations were not made or tested. (D) Examples of point mutations in Myo2 with defects in binding cargo adaptors that may act by affecting the structure of the Myo2 CBD. (inset) Myo2-G1248 is a buried residue, which is consistent with G1248D affecting the binding of multiple adaptor proteins. Myo2-L1301 and Myo2-P1529 are surface residues. Although L1301 is surface exposed, the side chain is oriented toward helix 4. This likely explains why L1301R and L1301P affect the ability of Myo2 to interact with Vac17 and Mmr1 (Fig. 1 A). To date, P1529S/A solely perturbs Mmr1 binding, which suggests that it is part of the Mmr1-binding region. (E) The *mmr1Δ* mutant exhibits a greater mitochondrial inheritance defect than either *ypt1Δ* or *myo4Δ* mutants. Wild-type (MYO2) or the indicated deletion mutant strains were transformed with mitoGFP (*LEU2*) and grown for at least six doubling times before imaging. The absence or presence as well as the position of mitochondria in the bud was scored in small and medium budded cells. Categories I and IV were mutant; categories II and III were wild type-like. *n* = 2; ≥200 cells per strain. (F) Mmr1 and Ypt11 interact with Myo2, but not with each other, in a yeast two-hybrid test. (A, D, and F) Two-hybrid plates incubated at 24°C for 3–4 d. Top left squares in each panel are empty vector controls.





Figure S2. **Mmr1 and Vac17 peptides that bind Myo2 CBD.** Use of two-hybrid analysis to predict peptides of Mmr1 and Vac17 that will interact with Myo2 but not myo2 mutants that are defective in binding Vac17 and Mmr1 in vivo, respectively. Two-hybrid plates incubated at 24°C for 3–5 d. Top left squares in each panel are empty vector controls. The ePEST FIND algorithm on the Mobylye portal (Pasteur Institute) was used for identification of *MMR1* and *VAC17* PEST sequences. AD, activation domain; BD, binding domain.



B

Category:	I		II		III		IV		V		Total	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
Allele												
MYO2	57	25.6	25	11.2	69	30.9	24	10.8	48	21.5	223	100
<i>myo2-G1248D</i>	20	8.5	64	27.2	63	26.8	11	4.7	77	32.8	235	100
<i>myo2-N1304D</i>	63	24.7	27	10.6	81	31.8	29	11.4	55	21.6	255	100
<i>myo2-L1331S</i>	19	8.8	75	34.9	47	21.9	24	11.2	50	23.3	215	100
<i>myo2-F1334A</i>	27	12.5	69	31.9	60	27.8	12	5.6	48	22.2	216	100
<i>myo2-W1407F</i>	40	17.7	71	31.4	52	23.0	25	11.1	38	16.8	226	100
<i>myo2-K1408A</i>	22	8.9	73	29.7	49	19.9	28	11.4	74	30.1	246	100
<i>myo2-L1411R</i>	52	25.4	49	23.9	55	26.8	17	8.3	32	15.6	205	100
<i>myo2-N1414S</i>	60	27.6	27	12.4	61	28.1	25	11.5	44	20.3	217	100
<i>myo2-Y1415E</i>	38	17.8	68	31.8	39	18.2	26	12.1	43	20.1	214	100
<i>myo2-Y1415F</i>	46	20.1	63	27.5	67	29.3	15	6.6	38	16.6	229	100
<i>myo2-T1418V</i>	91	33.1	45	16.4	67	24.4	16	5.8	56	20.4	275	100
<i>myo2-R1419Q</i>	67	27.9	30	12.5	64	26.7	28	11.7	51	21.3	240	100
<i>myo2-K1444A</i>	57	26.3	22	10.1	72	33.2	19	8.8	47	21.7	217	100
<i>myo2-Q1447R</i>	54	25.6	22	10.4	63	29.9	27	12.8	45	21.3	211	100
<i>myo2-I1462S</i>	78	34.5	41	18.1	55	24.3	13	5.8	39	17.3	226	100
<i>myo2-D1482N</i>	61	28.5	30	14.0	66	30.8	14	6.5	43	20.1	214	100
<i>myo2-Y1483A</i>	29	12.7	67	29.4	60	26.3	19	8.3	53	23.2	228	100
<i>myo2-Y1484A</i>	80	30.1	37	13.9	73	27.4	21	7.9	55	20.7	266	100

Figure S3. **Determination of the surface residues on Myo2 that comprise the Rab/Inp2/Kar9 binding sites.** (A) Surface representation of the crystal structure of the Myo2 CBD. Colored residues (except dark green) indicate those sites that when mutated had defects in their ability to interact with any of the Rab GTPases, Kar9, or Inp2. Red: Inp2 only; orange: Kar9 and Inp2; yellow: Kar9 only; green (Myo2-L1331 only): Kar9, Sec4, and Ypt31/32; blue: Sec4, Ypt11, and Ypt31/32; brown: Kar9, Inp2, Sec4, Ypt11, and Ypt31/32. Dark green residues were those tested for Rab GTPases, Kar9, or Inp2 that did not affect binding. These are numbered consistent with Fig. S1 A: 9, 1,297; 15, 1,304; 16, 1,307; 17, 1,308; 20, 1,331; 21, 1,408; 22, 1,411; 23, 1,414; 24, 1,415; 25, 1,418; 26, 1,422; 27, 1,444; 28, 1,447; 31, 1,480; 32, 1,482; 33, 1,483; 34, 1,484; 35, 1,525; 36, 1,526; 38, 1,529; 39, F1,334; 40, W1,407; 41, R1,419; 42, I1,462; and 43, L1,539. (B) Residues that disrupt the Kar9 interaction with Myo2 in a yeast two-hybrid test also disrupted the orientation of spindle microtubules in vivo. Category I: spindle oriented. Category II: spindle misoriented. Category III: microtubules pointed into the focal plane of the image. Category IV: microtubules were near or at the mother-bud neck region. Category V: nuclei were already undergoing separation. Only categories I and II are informative, but all cells were scored, and the results are shown. *n*, number of cells counted from at least two independent experiments. Bar, 5 μ m.

References

- Catlett, N.L., and L.S. Weisman. 1998. The terminal tail region of a yeast myosin-V mediates its attachment to vacuole membranes and sites of polarized growth. *Proc. Natl. Acad. Sci. USA*. 95:14799–14804. <http://dx.doi.org/10.1073/pnas.95.25.14799>
- Fagarasanu, A., F.D. Mast, B. Knoblach, Y. Jin, M.J. Brunner, M.R. Logan, J.N. Glover, G.A. Eitzen, J.D. Aitchison, L.S. Weisman, and R.A. Rachubinski. 2009. Myosin-driven peroxisome partitioning in *S. cerevisiae*. *J. Cell Biol.* 186:541–554. <http://dx.doi.org/10.1083/jcb.200904050>
- Frederick, R.L., K. Okamoto, and J.M. Shaw. 2008. Multiple pathways influence mitochondrial inheritance in budding yeast. *Genetics*. 178:825–837. <http://dx.doi.org/10.1534/genetics.107.083055>
- Ishikawa, K., N.L. Catlett, J.L. Novak, F. Tang, J.J. Nau, and L.S. Weisman. 2003. Identification of an organelle-specific myosin V receptor. *J. Cell Biol.* 160:887–897. <http://dx.doi.org/10.1083/jcb.200210139>
- James, P., J. Halladay, and E.A. Craig. 1996. Genomic libraries and a host strain designed for highly efficient two-hybrid selection in yeast. *Genetics*. 144:1425–1436.
- Jin, Y., P. Taylor Eves, F. Tang, and L.S. Weisman. 2009. PTC1 is required for vacuole inheritance and promotes the association of the myosin-V vacuole-specific receptor complex. *Mol. Biol. Cell*. 20:1312–1323. <http://dx.doi.org/10.1091/mbc.E08-09-0954>
- Pashkova, N., N.L. Catlett, J.L. Novak, and L.S. Weisman. 2005. A point mutation in the cargo-binding domain of myosin V affects its interaction with multiple cargoes. *Eukaryot. Cell*. 4:787–798. <http://dx.doi.org/10.1128/EC.4.4.787-798.2005>
- Pashkova, N., Y. Jin, S. Ramaswamy, and L.S. Weisman. 2006. Structural basis for myosin V discrimination between distinct cargoes. *EMBO J*. 25:693–700. <http://dx.doi.org/10.1038/sj.emboj.7600965>
- Sheffield, P., S. Garrard, and Z. Derewenda. 1999. Overcoming expression and purification problems of RhoGDI using a family of “parallel” expression vectors. *Protein Expr. Purif.* 15:34–39. <http://dx.doi.org/10.1006/prep.1998.1003>
- Sikorski, R.S., and P. Hieter. 1989. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in *Saccharomyces cerevisiae*. *Genetics*. 122:19–27.
- Song, S., and K.S. Lee. 2001. A novel function of *Saccharomyces cerevisiae* CDC5 in cytokinesis. *J. Cell Biol.* 152:451–469. <http://dx.doi.org/10.1083/jcb.152.3.451>
- Tang, F., E.J. Kauffman, J.L. Novak, J.J. Nau, N.L. Catlett, and L.S. Weisman. 2003. Regulated degradation of a class V myosin receptor directs movement of the yeast vacuole. *Nature*. 422:87–92. <http://dx.doi.org/10.1038/nature01453>

Table S1 shows yeast strains used in this study and is provided as an Excel file.

Table S2 shows plasmids used in this study and is provided as an Excel file.

Table S3 shows a summary of yeast two-hybrid and in vivo analyses and is provided as an Excel file.